NEWS FLASH!!
Morningstar has upgraded its share price target for PNV.
Morningstar initiated coverage of PNV in September last year, when the share price was ~$1.30, allocating a fair share price value of $1.00. Since then, the Morningstar equity analyst, Shane Ponraj, hasn’t revised his assessment of the company’s fair value.
The good news is that, since Morningstar’s last report on July 25, and with the share price now ~$2.30, the analyst seems to be finally warming to PNV.
In the latest report on PNV, released today, Ponraj concedes that “Polynovo is growing quickly. Fiscal 2024 sales rose 54% to $92 million, 2% ahead of our forecast, with 75% stemming from the main United States market. The shares are up more than 68% in the last year.”
Consequently, Morningstar has raised its fair value estimate by 5% to $1.05 “primarily due to the time value of money and slightly higher revenue forecasts” and revised its forecast five-year revenue compound annual growth rate increases from 25% to 26%.
Phew!!!
- Forums
- ASX - By Stock
- PNV
- PNV Media Thread
PNV
polynovo limited
Add to My Watchlist
0.85%
!
$1.17

PNV Media Thread, page-3240
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.17 |
Change
-0.010(0.85%) |
Mkt cap ! $804.8M |
Open | High | Low | Value | Volume |
$1.18 | $1.20 | $1.16 | $2.306M | 1.970M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 12793 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 1.180 |
1 | 4000 | 1.170 |
2 | 71810 | 1.160 |
3 | 57000 | 1.155 |
13 | 89983 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 23 | 1 |
1.150 | 268 | 2 |
1.160 | 1539 | 2 |
1.180 | 7407 | 1 |
1.190 | 800 | 1 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online